Acquisition enhances ICON's site and patient engagement
capabilities
DUBLIN--(BUSINESS WIRE)--
ICON
plc, (NASDAQ: ICLR) a global provider of drug development
solutions and services to the pharmaceutical, biotechnology and medical
device industries, today announced the acquisition of PMG Research,
Inc., an integrated network of clinical research sites operating from 12
metropolitan areas throughout the US. The acquisition will enhance
ICON's ability to access and engage with investigator sites and
patients, helping customers to reduce the overall time and cost
associated with drug development.
PMG Research is an integrated network of clinical research sites
consisting of 48 physician practices and large multi-specialty
healthcare institutions throughout North Carolina, South Carolina,
Tennessee and Illinois. PMG Research conducts clinical trials in all
major therapeutic areas with particular experience in cardiology,
dermatology, endocrinology, gastroenterology, men's health, neurology,
pulmonology, rheumatology, vaccine, and women's health trials. In
addition to a proprietary research database of clinical trial
participants, PMG Research also has access to over 2 million active
patient lives via electronic health records through their unique
partnerships with healthcare systems and community physician practices.
Commenting on the acquisition, Ciaran Murray said: "Enrolling and
engaging patients in clinical trials is a key challenge within drug
development. Leveraging PMG Research's network, we will help customers
to enhance clinical trial feasibility and improve patient enrolment
timelines whilst also giving patients access to a broader range of care
options through clinical trials. Today's acquisition, together with our
work with IBM Watson on clinical trial matching, reflects our commitment
to enhancing engagement with sites, patients and healthcare providers to
take significant time and cost from our customers' development
programmes."
Jennifer Byrne, CEO of PMG Research, states, "ICON shares PMG's
progressive views and by combining together we can enhance our ability
to scale our know-how, infrastructure, and health care relationships to
bring more of the right trials to the right patients. Together we will
enhance the execution of clinical trials and deliver greater value for
both the industry and health care systems, forging better and closer
connections. The ultimate beneficiary of this work will be patients
through lower cost of care, improved clinical outcomes and enhanced
patient experiences."
About PMG Research, Inc.
PMG Research, Inc. is an integrated network of clinical research
facilities with 12 hub supersites located in Champaign, IL; Cary,
Charlotte, Hickory, Raleigh, Rocky Mount, Salisbury, Wilmington, and
Winston-Salem, NC; Charleston, SC; and Bristol and Knoxville, TN. PMG
has conducted over 7,500 research studies for hundreds of pharmaceutical
sponsors and CROs since 1979. PMG's mission is to bring clinical
research to as many lives as possible while delivering unparalleled
service and exceptional value to clinical trial partners and
stakeholders. Further information is available at www.pmg-research.com.
About ICON plc
ICON plc is a global provider of drug development solutions and services
to the pharmaceutical, biotechnology and medical device industries. The
company specialises in the strategic development, management and
analysis of programs that support clinical development - from compound
selection to Phase I-IV clinical studies. With headquarters in Dublin,
Ireland, ICON currently, operates from 77 locations in 38 countries and
has approximately 11,700 employees.
Further information is available at www.iconplc.com.
This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and industry
conditions. These statements are not guarantees of future performance or
actual results, and actual results, developments and business decisions
may differ from those stated in this press release. The forward-looking
statements are subject to future events, risks, uncertainties and other
factors that could cause actual results to differ materially from those
projected in the statements, including, but not limited to, the ability
to enter into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the integration of
new business mergers and acquisitions, as well as economic and global
market conditions and other risks and uncertainties detailed from time
to time in SEC reports filed by ICON, all of which are difficult to
predict and some of which are beyond our control. For these reasons, you
should not place undue reliance on these forward-looking statements when
making investment decisions. The word "expected" and variations of such
words and similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they are
made and we do not undertake any obligation to update publicly any
forward-looking statement, either as a result of new information, future
events or otherwise. More information about the risks and uncertainties
relating to these forward-looking statements may be found in SEC reports
filed by ICON, including its Form 20-F, F-1, S-8 and F-3, which are
available on the SEC's website at http://www.sec.gov.
ICON/ICLR-F
View source version on businesswire.com: http://www.businesswire.com/news/home/20151207005550/en/
ICON Media Contact
Weber Shandwick
Rosie Ireland, +44
(0) 207 067 0190
RIreland@webershandwick.com
Source: ICON plc
News Provided by Acquire Media
